Changing strategies in the management of acute myocardial infarction in modern China

CVD Prevention and Control

Volumn 4, Issue 1, 2009, Pages 9-18

  Chen, Zhengming ^a   Jiang, Lixin ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FUWAI HOSPITAL   (China)

Author keywords

China; Management; Myocardial infarction; Randomised trial; Registry

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; NITRATE; PLACEBO; REVIPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; XUEZHIKANG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; CHINA; CLINICAL TRIAL; CORONARY REPERFUSION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HEART REINFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LENGTH OF STAY; MORTALITY; PATIENT COUNSELING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SECONDARY PREVENTION; SMOKING CESSATION; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VASCULAR PATENCY;

EID: 60749131692     PISSN: 18754570     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvdpc.2008.07.006     Document Type: Article

References (30)

1. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiological transition, risk factors, and impact of urbanisation. Circulation 104 (2001) 2746-2753
2. He J., Gu D., Wu X., et al. Major causes of death among men and women in China. N Engl J Med 353 (2005) 1124-1134
3. Wu Z.S., Yao C.H., Zhao D., Wu G.X., Wang W., Liu J., et al. Sino-MONICA Project: a collaborative study on trends and determinants of cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation 103 (2001) 462-468
4. The Ministry of Health. China health statistics year book (2005), Publishing House of Peking Union Medical College, Beijing
5. Murray C.J.L., and Lopez A.D. The global burden of disease (1996), Harvard School of Public Health, Boston, Mass
6. Beijing CHD Collaborative Group. Changes in the case fatality of hospitalised patients with acute MI in Beijing from 1977-86. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 18 4 (1990) 215-216
7. Chinese Cardiac Study Collaborative Group. Preliminary results of first Chinese cardiac study of oral captopril versus placebo among 13,600 patients with suspected acute myocardial infarction (CCS-1). Lancet 345 (1995) 686-687
8. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1606-1621
9. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
10. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
11. Yang Y.M., Zhu J., Tan H.Q., Liang Y., Zhang Y., Li J.D., et al. Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases. Nat Med J Chin (Zhonghua Yi Xue Za Zhi) 85 (2005) 2176-2182
12. Yu L.T., Zhu J., Mister R., Zhang Y., Li J.D., Wang D.L., et al. The Chinese registry on reperfusion strategies and outcomes in ST-elevation myocardial infarction. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 34 (2006) 593-597
13. Rogers W.J., Canto J.G., Lambrew C.T., Tiefenbrunn A.J., Kindaid B., Shoultz D.A., et al. Temporal trends in the treatment of over 1. 5 million patients with myocardial infarction in the US from 1990 through 1999. J Am Coll Cardiol 36 (2000) 2056-2063
14. Fox K.A.A., Goodman S.G., Klein W., Brieger D., Steg P.G., Dabbous O., et al. Management of acute coronary syndromes. Variations in practice and outcome: findings from the global registry of acute coronary events (GRACE). Eur Heart J 23 (2002) 1177-1189
15. Hasdai D., Behar S., Wallentin L., Nanchin N., Gitt A.K., Boersma E., et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro heart survey of acute coronary syndromes (Euro heart survey ACS). Euro Heart J 23 (2002) 1190-1201
16. Ross A.M., Gao R.L., Coyne K.S., Chen J.L., Yao K.B., Yang Y.J., et al. A randomised trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial. Am Heart J 142 (2001) 244-247
17. Kawai C., Yoshiki Y., Hosoda S., et al. A prospective, randomised double-blind multicentre trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. J Am Coll Cardiol 29 (1997) 1447-1453
18. Chinese Society of Cardiology. A data analysis of the third national coronary intervention registry. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 30 (2002) 719-723
19. CHANCE Study Group. The immediate and long-term prognosis following unprotected left main coronary artery stenting in Chinese. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 33 (2005) 210-215
20. Gao RL, Patel A, Gao W, Hu DY, Huang DJ, Kong LZ, et al. Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes. Heart; 2007 [published on line on Oct 11, 2008;94:554-60.
21. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A radomised placebo controlled international trial. Eur Heart J 6 (1985) 199-211
22. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
23. Pfisterer M., Cox J.L., Granger C.B., et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The GUSTO-I experience. J Am Coll Cardiol 32 (1998) 634-640
24. Zhou H.H., Koshakji R.P., Silberstein D.J., Wilkinson G.R., and Wood A.J.J. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med 320 (1989) 565-570
25. COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
26. Chinese Coordinating Centre of OASIS Registry. The clinical characteristics of acute coronary syndrome in China. Chin J Inter Med (Zhonghua Nei Ke Za Zhi) 42 (2003) 697-700
27. Tan H.Q., Zhu J., Liang Y., Zhang Y., and Liu L.S. Two year follow-up of acute ischaemic syndrome without ST elevation. Nat Med J Chin (Zhonghua Yi Xue Za Zhi) 85 (2005) 184-188
28. Lu Z.L. Collaborative group for china coronary secondary prevention using Xuezhikang. China coronary secondary prevention study (CCSPS). Chinese J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 33 (2005) 109-115
29. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: meta-analysis of individual data from 90,056 participants in 14 randomised trials of statin. Lancet 366 (2005) 1267-1278
30. Wang H.L., Xu T.D., and Xu J. Factors contributing to high costs and inequality in China's health care system. JAMA 298 (2007) 1928-1930